Katya C Corado

Katya C Corado, MD is a Clinical Associate Professor in the Department of Internal Medicine at Charles R. Drew University of Medicine and Science. She is actively engaged in research on HIV prevention, medication adherence, and public health interventions, particularly focusing on vulnerable populations such as transgender individuals and men who have sex with men (MSM).

Her research interests span HIV pre-exposure prophylaxis (PrEP), behavioral sciences, medication adherence, sexually transmitted infections, pharmacology, and digital health interventions. She has extensively studied adherence technologies, risk compensation behaviors, and barriers to PrEP initiation and persistence, especially among marginalized communities.

The analysis of her recent publications reveals a strong focus on clinical trials, public health implementation, and behavioral determinants of HIV prevention. Her work frequently involves randomized controlled trials, cohort studies, and multi-site collaborations, often through the California Collaborative Treatment Group (CCTG). Themes include digital adherence tools (e.g., ingestible sensors, text messaging), mental health impacts (e.g., gender-based violence, PTSD), and biological monitoring (e.g., bone turnover, STI screening).

• Condomless Sex With Virologically Suppressed HIV-Infected Individuals: How Safe Is It? (JAMA, 2016)
• Emtricitabine + tenofovir alafenamide for the treatment of HIV (Expert Opin Pharmacother, 2017)
• Randomized Controlled Trial of Daily Text Messages to Support Adherence to PrEP (Clin Infect Dis, 2018) – cited 55 times
• Safety and Efficacy of Monoclonal Antibodies for COVID-19 (Pathog Immun, 2024)

Dr. Corado has been involved in numerous advisory and collaborative roles within large-scale research initiatives, though no formal students or awards are listed in the available data. She has contributed to health coaching interventions, substance use studies, and policy-relevant research that has been cited in news outlets and public health discussions. Her work demonstrates a commitment to reducing HIV transmission through innovative, evidence-based, and equitable strategies.

She is affiliated with research teams investigating long-term PrEP adherence, sexual risk behaviors, and novel pharmacotherapies for HIV. Her collaborations extend across institutions and disciplines, reflecting an interdisciplinary approach to infectious disease prevention and health equity.